In this study we demonstrate that R70 and SyH7, two well-characterized monoclonal antibodies (mAbs) directed against distinct epitopes on the surface of ricin's enzymatic subunit (RTA), interfere with toxin transport from the plasma membrane to the trans Golgi network. Toxin-mAb complexes formed on the cell surface delayed ricin's egress from EEA-1
Scientific RepoRts | 6:22721 | DOI: 10.1038/srep22721 toxin-neutralizing activity 9, 10 . The mAb SyH7 defines a second immunodominant region on RTA (Supplementary Table 1) 10 . SyH7 recognizes a linear epitope spanning residues 187-198 and is equally potent at neutralizing ricin toxin in vitro as R70 10 . We recently described three other SyH7-like mAbs, each with the capacity to passively protect mice against ricin toxin challenge 9 . It remains unclear how RTA-specific mAbs like R70 and SyH7 neutralize ricin. It has been proposed that R70-like antibodies may affect RTA's RNA N-glycosidase activity through distortion of α -helix B 11 . While there is evidence to suggest R70 marginally impacts RTA's enzymatic activity in cell free in vitro translation assays 8 , it seems unlikely that R70 would ever encounter RTA in the cytoplasm, considering that RTA only reaches its final destination as a consequence of retrograde transport and retro-translocation. Rather, we think it more likely that R70 and SyH7 interfere with an upstream event in the intoxication process. Pincus and colleagues suggested that certain toxin-neutralizing, RTA-specific murine mAbs delay toxin internalization and/or interfere with intracellular trafficking to the ER 12 . We concur with this model and, based on numerous studies from our group, would argue more specifically that ricin RTA-specific mAbs likely influence very upstream events in the retrograde trafficking pathway, ultimately impairing delivery of ricin to the TGN [13] [14] [15] [16] . In the current study we demonstrate using a combination of confocal microscopy and TGN-specific labeling methods that R70 and SyH7, as well as three other toxin-neutralizing RTA-specific mAbs impair retrograde trafficking of ricin to the TGN.
Results
Uptake and intracellular trafficking of R70-and SyH7-toxin complexes into adherent cells. To examine whether R70 and SyH7 are internalized into cells in complex with ricin, Vero cells were grown overnight on glass coverslips and then incubated with FITC-labeled ricin holotoxin for 30 min at 4 °C to allow toxin binding but not endocytosis. The cells were then washed to remove unbound toxin, treated with R70 or SyH7 for additional 30 min at 4 °C and then shifted to 37 °C to permit toxin internalization. At time points thereafter (30 min, 90 min and 4 hr), the cells were fixed, probed with DyLight ® 549 anti-mouse IgG and visualized by confocal laser scanning microscopy (CLSM). We observed that R70-and SyH7-toxin complexes were internalized and trafficked intracellularly in Vero cells, as evidenced by colocalized staining of ricin (green) and R70 or SyH7 (red) at each of the three time points examined ( Fig. 1; Supplementary Fig. 2 ). At the 30 min time point, toxin-mAb complexes were situated within vesicles that were distributed throughout the cytoplasm. By 90 min, the toxin-mAb complexes resided within vesicles that had localized around the nucleus. By 4 hr, vesicles containing toxin-mAb and imaged by confocal microscopy. In the images, ricin appears green, R70 is red, a merge between ricin and R70 is yellow, and the cell nucleus is blue. Insets in the right and left hand columns highlight the subcellular localization of ricin (white arrowheads) and ricin-R70 complexes (black arrowheads). Images are representative of at least 5 independent experiments. Scale bar, 5 μm.
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To determine whether R70 and SyH7 interfere with transport of ricin to the TGN, Vero cells were treated with mAb-ricin complexes and then subjected to immuno-labeling with Golgin97 (Fig. 2) . The trafficking of ricin to the TGN was significantly impaired by R70 and SyH7 (50-60%; p < 0.05) ( Fig. 2A-C) but not FGA12, a non-neutralizing RTA-specific isotype control mAb 10, 15 ( Supplementary Fig. 3 ). It should be acknowledged that the failure of FGA12 to interfere with intracellular ricin transport is likely due to FGA12's low affinity for soluble toxin and not necessarily related to epitope specificity per se.
To better quantitate the effects of R70 and SyH7 on ricin toxin retrograde trafficking, we employed an organelle-specific sulfation assay in which a derivative of RTA known as RS1 (~30 kDa) becomes modified upon entry into the TGN by resident tyrosylprotein sulfotransferases 17 . RS1 holotoxin was mixed with R70 or SyH7 and then applied to HeLa cells for two hours, after which the cells were washed with lactose to remove surface-associated ricin and then lysed to measure the degree of RS1 sulfation by autoradiography. Sulfation of RS1 was significantly impaired by R70 (> 85% reduction) and SyH7 (> 60% reduction), but not the non-neutralizing mAb, FGA12 (Fig. 3A,B) . The same effect on RS1 sulfation was observed when the experiments were repeated in Vero cells, although SyH7's effects on RS1 trafficking were slightly more severe (> 85%) than was observed in HeLa cells (Supplementary Fig. 3B ). These results are consistent with R70 and SyH7 each having an effect on ricin toxin retrograde transport R70 and SyH7 recognize so-called epitope clusters 1 and 2 on the surface of RTA 9 . We wished to examine what effect other toxin-neutralizing, RTA-specific mAbs, notably IB2 and GD12, which are directed against epitope clusters 3 and 4, have on ricin retrograde transport. IB2 tentatively recognizes a discontinuous epitope at the interface of RTA and RTB, while GD12 recognizes a linear epitope spanning residues α -helix E (residues 163-174) (Supplementary Table 1 ; Supplementary Fig. 1 ). We also wished to examine the effect of PB10 on ricin retrograde transport; PB10 is an R70-like mAb that is of interest because it has been fully humanized and is being evaluated as a possible therapeutic for ricin intoxication 7, 18 . For the sake of licensure purposes, it will be critical to be able to document exactly how PB10 actually neutralizes ricin toxin.
We employed the RS1 sulfation assay to evaluate quantitatively the effect that IB2, GD12 and PB10 have on ricin toxin uptake and retrograde transport to the TGN. As noted above, RS1 holotoxin was mixed with each individual mAb and then applied to HeLa cells that had been grown in the presence of 35 SO 4 2− . We found that IB2, GD12 and PB10 each impaired RS1 sulfation by > 80% (Fig. 3A,B) . Finally, Western blot analysis of total cell lysates indicated that R70 and SyH7, as well as IB2, GD12 and PB10 actually enhanced (~2-fold) the amount of ricin that was associated with HeLa cells after a 2 hr incubation period, as compared to ricin treated control cells (Fig. 3C,D) . Although these differences were not statistically significant (i.e., p > 0.05, as compared to ricin-treated control cells) they do suggest that the mAbs influence the amount of ricin retained on the cell surface or that is internalized by endocytosis. This issue will be discussed in more detail later in the manuscript. Supplementary Fig. 4 ), indicating that expulsion of toxin-antibody complexes via RE is not enhanced.
R70-and
Based on these observations we speculated that R70 and SyH7 might promote the trafficking of ricin to lysosomes for degradation. To address this experimentally, Vero cells were treated with 10 mM NH 4 Cl, an inhibitor of endosome-lysosome acidification, prior to being challenged with R70-and SyH7-toxin complexes. Cells were fixed 4.5 hr later and visualized by confocal microscopy. In the absence of NH 4 Cl, ricin-mAb complexes were detected within small diffusely localized vesicles that were only moderately fluorescent, possibly indicative of ricin-mAb complexes undergoing lysosome-mediated degradation. In contrast, NH 4 Cl treatment resulted in the accumulation of ricin-mAb complexes in large, fluorescently bright vesicles ( Supplementary Fig. 5 ). Immunolabeling confirmed that the vesicles were positive for Lamp-1, a well-recognized marker of lysosomes (Fig. 6A) . The large size of the vesicles was likely due to swelling of the lysosomes caused by NH 4 Cl treatment and not ricin accumulation, because lysosomotropic compounds like NH 4 C are known to promote lysosome enlargement and swelling 14, 19, 20 . In the presence of NH 4 Cl, ricin-mAb complexes were more frequently associated with LAMP-1 + and Rab7 + vesicles than was ricin alone (Figs. 6B and 7), supporting a model in which ricin-mAb complexes are preferentially shunted to lysosomes for degradation.
Interference of ricin toxin retrograde transport by vaccine-induced immune sera. RiVax is candidate ricin toxin subunit vaccine consistning of a full-length, non-toxic recombinant derivative of RTA 21 . RiVax vaccination of mice elicits high levels of circulating RTA-specific antibodies that protect mice against lethal toxin challenge 22 . However, the mechanism(s) by which anti-ricin and anti-RiVax polyclonal antibodies neutralize ricin has not been investigated. To address the possibility that polyclonal anti-RTA antisera impact ricin retrograde trafficking, ricin-FITC was mixed with antiserum from a mouse treated three times with sub-lethal doses of ricin (unpublished results) or antiserum from a mouse vaccinated with RiVax 23 . The antibody/ricin-FITC mixtures were applied to Vero cells at 4 °C and then shifted to 37 °C to permit internalization. Examination of cells at 90 min and 4 hr time points revealed that each antiserum impacted toxin trafficking profiles (Fig. 8) . At 90 min, ricin that had been treated with antisera was present in vesicles that were larger and brighter than ricin without antibody treatment. By 4 hr, there was little to no detectable intracellular ricin in cells that had been treated with ricin or RiVax antisera, suggesting the toxin-antibody complexes had been cleared from the cell through lysosomal degradation.
Discussion
Ricin toxin's enzymatic subunit, RTA, is at the center of efforts to develop a safe and effective ricin toxin subunit vaccine for use by military personnel, laboratory research staff, and emergency first responders 5, 24, 25 . Chimeric and fully humanized RTA-specific mAbs are also being pursued as possible therapeutics to treat individuals suffering ricin intoxication 5, 18 . Despite the increased interest in ricin's enzymatic subunit, it remains largely unclear how RTA-specific antibodies neutralize ricin toxin. Two reports published in 2013 suggested that RTA-specific mAbs likely neutralize ricin toxin intracellularly, rather than extracellularly 12, 15 . We demonstrated by confocal microscopy that ricin-IB2 complexes are internalized into Vero cells, although the effects of the antibody on retrograde trafficking were not investigated 15 . Song and colleagues used live cell imaging to track the kinetics of ricin uptake into HeLa cells in the presence of the neutralizing mAb RAC18 12 . They observed that RAC18 was internalized into host cells with ricin and delayed the toxin trafficking to the ER.
In the current study we have now refined those two previous reports and demonstrate that two well-characterized mAbs, R70 and SyH7, as well as three additional toxin-neutralizing mAbs, GD12, IB2 and PB10, interfere with ricin retrograde transport from the plasma membrane to the TGN, presumably by shunting ricin to lysosomes for degradation. The five mAbs recognize at least four spatially distinct epitopic regions on the surface of RTA: R70 and PB0 bind linear epitopes on the "front side" of RTA focused around α -helix E (residues 97-108), while SyH7 recognizes a linear epitope on the "back side" of RTA around α -helix F (187-198). GD12 binds a linear epitope spanning residues 163-174 that corresponds to α -helix E 8 . The exact epitope recognized by IB2 is not known, but is postulated to span the interface between RTA and RTB 15 . Although we demonstrated that five different RTA-specific mAbs can interfere with ricin toxin retrograde transport, we have not elucidated the mechanism(s) by which this occurs. It is possible that physical association of a single mAb (1:1 antibody:toxin ratio) with one or two molecules (1:2 antibody:toxin ratio) of ricin may be sufficient to derail toxin trafficking. It was shown many years ago that a monovalent ricin-HRP conjugate (30 kDa) C-methylated protein molecular weight standard, were subjected to SDS-PAGE and transferred to a PVDF membrane. Specific RTA sulfation was measured by autoradiography (A) and quantitated by densitometry (B). Total sulfation was determined by precipitation of the remaining lysate. Each bar (mean with SD) represents the average of three independent experiments. The asterisks (p < 0.01) represent significance between % sulfated ricin control and sulfated ricin plus mAb treatment, as determined using an unpaired t-test with a 95% confidence interval. While there were slight differences in total sulfation across the different treatment groups (100-115%), none of the differences observed were statistically significant. After the sulfation assay, the membrane was subjected to Western blot analysis with an anti-RTA antibody (C) and then quantitated by densitometry (D). The densitometry signals in presence of mAbs were normalized to the signal for RS1 alone, which was set to 100%. does not alter retrograde transport, but polyvalent ricin-HRP or colloidal gold conjugates did, suggesting that valency and/or size of the conjugate affects how the cell sorts the toxin 16 . Unfortunately, we now know that our choice of FGA12 as a non-neutralizing negative control mAb in this study does not help resolve the issue of whether or not the association of a mAb with ricin is sufficient to interfere with trafficking. When first described, FGA12 was characterized as being able to bind RTA by ELISA but devoid of any detectable toxin-neutralizing activity in vitro or in vivo 10 . Pepscan analysis revealed that FGA12 recognizes a linear epitope in RTA's N-terminus (residues 37-48). Based on these attributes, we rationalized that FGA12 would serve as an ideal control for the present study (i.e., binds ricin but fails to neutralize). However, in the past year we have discovered that FGA12 recognizes a "cryptic" epitope on RTA that is exposed when RTA or ricin is adsorbed to polystyrene microtiter ELISA plates, but that is sequestered on RTA or ricin in solution (J. O'Hara, D. Vance, and N. Mantis, manuscript in preparation). As such, FGA12 fails to recognize ricin in solution. Two other non-neutralizing mAbs, SB1 and BD12 share the same characteristics (e.g., recognize cryptic epitopes) even though all three mAbs recognize different epitopes 10 . The upshot of this is that we cannot formally exclude the possibility that the association any mAb to the surface of RTA (irrespective of epitope) is sufficient to affect ricin trafficking and thereby neutralizing the toxin.
Nonetheless, as shown in Fig. 3 , it is interesting that all five neutralizing mAbs tested in this study (i.e., R70, PB10, SyH7, GD12, and IB2) increased the amount of ricin that was associated with host cells after a two hour incubation period, followed by a lactose wash to remove surface bound toxin. Although these differences were not statistically significant (as compared to ricin alone), the numbers do suggest the mAbs influence the dynamics of ricin on the cell surface or within vesicular compartment(s). Song and colleagues suggested that the neutralizing mAb RAC18 promotes toxin accumulation on the cell surface and delays toxin uptake 12 . Our results are consistent with R70, PB10, SyH7, GD12, and IB2 having similar effects on ricin. As noted above, we are particularly interested in the possibility that neutralizing mAbs influence the valency of ricin at the cell membrane and, thus, alter receptor crosslinking and endocytosis 26 . Indeed, we have demonstrated that recombinant, bispecific camelid antibodies are particularly potent at neutralizing ricin in vitro and in vivo 27 . That said, crosslinking alone cannot explain toxin-neutralizing activity, as monovalent Fab fragments of R70, for example, are able to neutralize ricin as effectively as IgG 28 .
The results from the current study will have implications for the development of countermeasures against ricin toxin. As noted in the Results section, PB10 is of particular interest to us because it is being evaluated as a possible therapeutic for ricin intoxication. We previous described chimeric version of PB10 in which the murine V H and V L domains were grafted onto a human IgG1 framework 18 . The chimeric version of PB10 was expressed in a Nicotiana benthamiana-based rapid antibody-manufacturing platform (RAMP) that provides the potential for extremely fast and high-yield monoclonal antibody (MAb) production. Chimeric PB10 has potent ricin toin-neutralizing activity in vitro and in vivo, including the ability to rescue mice from the effects of ricin when administered up to 3 to 4 hr after toxin challenge. We have now produced a fully humanized version of PB10 in which the murine V H and V L framework regions have been mutated to conform with human consensus sequences (M. Pauly, L. Zeitlin, K. Whaley, E. Sully, G. Van Slyke, and N. Mantis, manuscript in preparation). The fully humanized version of PB10 completely neutralizes ricin in vitro and in mouse models of systemic and mucosal ricin challenge. We also demonstrate that anti-RiVax antiserum interferes with ricin retrograde transport in vitro, suggesting that this activity may be associated with vaccine-induced immunity to ricin. Future studies will be aimed at resolving exactly how mAbs and polyclonal antibodies affect trafficking of ricin within the endosomal system.
Methods
Chemicals, biological reagents, supplies and cell lines. Ricin toxin (Ricinus communis agglutinin II) and ricin-FITC were purchased from Vector Laboratories (Burlingame, CA). Tween-20, Triton X-100, and Hoechst 33342 were purchased from Sigma-Aldrich (St. Louis, MO). Commercial secondary and primary Abs are described in Supplementary Table 2. Glass coverslips (22 × 22 mm square, 1.5 mm) were purchased from Corning-Fischer Scientific (Suwanee, GA). Tissue culture-treated dishes (35 mm x 15 mm) were purchased from CELLTREAT Scientific Products (Shirley, MA). Cytofix/Cytoperm ™ Fixation/Permeabilization Solution was purchased from BD Biosciences (San Jose, California). Ammonium chloride was purchased from Sigma-Aldrich. HeLa and Vero cells were purchased from the American Type Culture Collection (Manassas, VA). Unless otherwise noted, all cell lines were maintained in a humidified incubator at 37 °C with a 5% CO 2 atmosphere.
Ricin mAbs and RiVax antiserum from mice. Murine mAbs have been described previously 10 and were purified from hybdridoma supernatants using ion-exchange (IEX) and protein G chromatography under endotoxin-free conditions. The R70 (also known as UNIVAX70/38) hybridoma was originally obtained from American Type Culture Collection (Manassas, VA). Archived RiVax antiserum was available from a previous study in which female BALB/c mice had been immunized with RiVax-adsorbed to Alhydrogel by the subcutaneous route and Use Program meets all of the standards required by law, and goes beyond the standards as it strives to achieve excellence in animal care and use.
Ricin-specific sulfation assays. Ricin-sulf-1 (RS1), ricin with a modified ricin A-subunit containing a tyrosine sulfation site, was produced and purified as described previously 17, 29 . HeLa and Vero cells were washed with sulfate-free HEPES-buffered medium supplemented with 2 mM L-glutamine, followed by incubation with 0.2 mCi/ml Na 2 35 SO 4 (Hartmann Analytic, Braunschweig, Germany) in sulfate-free HEPES-buffered medium for 2.5 hr at 37 °C. The radioelement 35S used in this study was handled according to the national guidelines given by the Norwegian Radiation Protection Authority. The work was performed in specific designated areas, using proper protective gear.
RS1 was pre-incubated with the indicated anti-RTA mAbs for 30 min at room temperature, before the mixture was applied to cells and incubated for 2 hr at 37 °C. The cells were then washed (2 × 5 min) with 0.1 M lactose in HEPES-buffered medium, and once in cold PBS on ice before the addition of 400 μl lysis buffer (0.1 M NaCl, 10 mM Na 2 HPO 4 , 1 mM EDTA, 1% Triton X-100, 60 mM octyl glycopyranoside) supplemented with complete protease inhibitors (Roche Diagnostics, Mannheim, Germany). The lysate was cleared by centrifugation (8000 rpm, 10 min, 4 °C) and 300 μl of the supernatant was mixed with 1 ml 5% trichloroacetic acid (TCA) followed by centrifugation at 14,000 rpm (10 min, 4 °C). The resulting pellet was washed once in ice-cold PBS, dissolved in 2x sample buffer and subjected to SDS-PAGE under reducing conditions, followed by blotting onto a PVDF membrane (Immobilon-P, Millipore, Billerica, MA, USA). A 14 C-methylated protein molecular weight standard ( 14 C Standard, PerkinElmer, Waltham, MA) was subject to SDS-PAGE alongside the cell lysates. The bands were detected by autoradiography using a PharosFX scanner and quantified using Quantity One ® 1-D Analysis Software (BioRad Laboratories Inc, Hercules, CA, USA). The total amount of sulfated proteins was determined by TCA-precipitation of the remaining lysates. For the purpose of quantification of ricin internalization after the sulfation assay, the resulting PVDF membrane was re-wet in PBS-T (PBS with 0.01% Tween-20) and then probed overnight at 4 °C with polyclonal anti-RTA antibody (Abcam, Cambridge, MA) in 5% BSA in PBS-T. The membrane was then repeatedly washed with PBS-T and probed with HRP-conjugated secondary antibody (Jackson Immunoresearch) that had been diluted in 1% BSA in PBS-T. The membrane were developed using ECL Western blotting detection reagent (GE Healthcare, Buckinghamshire, UK) and quantified using Quantity One ® 1-D Analysis Software (BioRad, Oslo, Norway). The densitometry signals in presence of antibodies were normalized to the signal for RS1 alone, which was set to 100%. 
